NCT06200558Recruiting
ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
Study wants to explore real-world data in three distinct settings * Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 534 (estimated)
- First submitted
- 3 Dec 2023
- Start date
- 31 Jan 2024
- Primary completion date
- 31 May 2024
- Lead sponsor
- Hospital of Macerata
- Diseases
- Prostate cancer
- NCT number
- NCT06200558
What you commit to
- Study type: Observational
- Planned participants: 534
- From 31 Jan 2024 to the primary completion date, 31 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients without histologically or radiologically confirmed metastatic disease and
- For ARON-3S
- ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section
- For ARON-3Lu
- ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC
- For ARON-3GEN
- Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
Other
- Patients without histologically confirmed diagnosis of PC
- HRD NEGATIVE STATUS
Who the study is looking for
- Patients aged \>18y
- Cytological or Histologically confirmed diagnosis of PC
- Histologically or radiologically confirmed diagnosis of metastatic disease and
- For ARON-3S
- ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)
- For ARON-3Lu
- ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC
- For ARON-3GEN
- HRD POSITIVE STATUS
- Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale Di Macerata Coordinator of this site? Confirm its status | Province of Macerata | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.